Sarepta Therapeutics, Inc. (SRPT)
NASDAQ: SRPT · Real-Time Price · USD
124.32
+2.73 (2.25%)
Jan 2, 2025, 3:19 PM EST - Market open
Sarepta Therapeutics Revenue
Sarepta Therapeutics had revenue of $467.17M in the quarter ending September 30, 2024, with 40.79% growth. This brings the company's revenue in the last twelve months to $1.64B, up 48.45% year-over-year. In the year 2023, Sarepta Therapeutics had annual revenue of $1.24B with 33.26% growth.
Revenue (ttm)
$1.64B
Revenue Growth
+48.45%
P/S Ratio
7.19
Revenue / Employee
$1,248,362
Employees
1,314
Market Cap
11.88B
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2023 | 1.24B | 310.32M | 33.26% |
Dec 31, 2022 | 933.01M | 231.13M | 32.93% |
Dec 31, 2021 | 701.89M | 161.79M | 29.96% |
Dec 31, 2020 | 540.10M | 159.27M | 41.82% |
Dec 31, 2019 | 380.83M | 79.80M | 26.51% |
Dec 31, 2018 | Pro | Pro | Pro |
Dec 31, 2017 | Pro | Pro | Pro |
Dec 31, 2016 | Pro | Pro | Pro |
Dec 31, 2015 | Pro | Pro | Pro |
Dec 31, 2014 | Pro | Pro | Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
UnitedHealth Group | 393.90B |
Johnson & Johnson | 87.70B |
Merck & Co. | 63.17B |
AbbVie | 55.53B |
AstraZeneca | 51.21B |
Novartis AG | 49.94B |
Thermo Fisher Scientific | 42.37B |
Abbott Laboratories | 41.22B |
SRPT News
- 1 day ago - Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Business Wire
- 12 days ago - Sarepta wins $115.2 million US drug patent verdict from Japan's Nippon Shinyaku - Reuters
- 15 days ago - Sarepta Therapeutics Completes Enrollment in EMERGENE, a Phase 3 Clinical Study of SRP-9003 for the Treatment of Limb-Girdle Muscular Dystrophy Type 2E/R4 - Business Wire
- 5 weeks ago - Sarepta Therapeutics Announces Global Licensing and Collaboration Agreement with Arrowhead Pharmaceuticals for Multiple Clinical and Preclinical siRNA Programs - Business Wire
- 7 weeks ago - Sarepta Therapeutics: BLA Filing Of SRP-9003 For LGMD Is The Next Step - Seeking Alpha
- 2 months ago - Sarepta Therapeutics, Inc. (SRPT) Q3 2024 Earnings Call Transcript - Seeking Alpha
- 2 months ago - Sarepta Therapeutics Announces Third Quarter 2024 Financial Results and Recent Corporate Developments - Business Wire
- 2 months ago - Sarepta Therapeutics to Announce Third Quarter 2024 Financial Results - Business Wire